AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06473259 — intervention group
Intervention type: DRUG
Intervention: Darolutamide Oral Tablet
Description: 600 mg/daily orally
Study NCT06473259 — intervention group
Intervention type: RADIATION
Intervention: radiotherapy
Description: radical radiotherapy on primary tumor
Study NCT06473259 — intervention group
Intervention type: DRUG
Intervention: Triptorelin
Description: 3,75 mg im/4 w
Study NCT04087252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor neoantigen
Description: tumor neoantigens
Study NCT01534949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 by intravenous \[IV\] infusion
Study NCT04100304 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: resection
Description: CT volumetry,liver function,biopsy before resection
Study NCT00478985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imatinib ending
Description: Interruption of the treatment by Imatinib
Study NCT02401594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
Study NCT02401594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
Study NCT03984591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone according to guidelines
Study NCT03984591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone according to guidelines
Study NCT00495755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath)
Description: An escalating dose given over 4 weeks
Study NCT02430324 — intervention group
Intervention type: OTHER
Intervention: posttraumatic cerebral infarction
Description: the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
Study NCT02723669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR10
Description: effervescent tablet
Study NCT02723669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylcysteine
Description: oral solution
Study NCT05513495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The effect of drip versus intermittent feeding on splanchnic oxygenation
Description: After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
Study NCT02436551 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT01425957 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Description: All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36).
Study NCT02558712 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Technology-based Eye Care Services (TECS) Protocol
Description: Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
Study NCT01351844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and exercise intervention
Description: An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
Study NCT01351844 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education and General Exercise
Description: A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
Study NCT04343599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Description: The first two sessions will have as objective the correct and effective learning of the hypopressive technique. The rest of the sessions will be dedicated to the realization of an exercise protocol based on a progression of postures from standing to supine. Diaphragmatic apneas of approximately 7 seconds will be performed, alternating each apnea with three breaths.
Study NCT00271609 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
Study NCT01410045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovariectomy
Description: Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
Study NCT01547000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered up to 8 weeks.
Study NCT01547000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release guanfacine (Intuniv)
Description: 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
Study NCT02312778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA Manipulation
Description: Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
Study NCT04438460 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood test
Description: For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery.
Study NCT04438460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery.
Study NCT00569088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbs formula
Description: The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days
Study NCT00569088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: 250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
Study NCT03604640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Physical exercise program and health education
Study NCT00753558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.
Description: Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel.
Study NCT00753558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.
Description: Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel.
Study NCT03352986 — intervention group
Intervention type: BIOLOGICAL
Intervention: biological analysis
Description: biological analysis will be performed in the 6 groups of patients
Study NCT01051414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, daily, 24 weeks
Study NCT01051414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 1200 mg, daily, 24 weeks
Study NCT01380847 — intervention group
Intervention type: GENETIC
Intervention: mRNAs encoding genes
Description: investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
Study NCT03352986 — intervention group
Intervention type: OTHER
Intervention: peripheral arterial tonometry
Description: peripheral arterial tonometry will be performed in the 6 groups of patients
Study NCT01748981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical training
Description: Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls
Study NCT01748981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: As usual
Description: Controls, not training
Study NCT02882854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Patients will receive 1 mg of guanfacine to take orally.
Study NCT02882854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
Study NCT00129493 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group medical visits
Description: Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
Study NCT00148889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation (DBS)
Description: Bilateral pallidal stimulation with an implanted DBS device
Study NCT00148889 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation (DBS)
Description: Bilateral pallidal stimulation with an implanted DBS device
Study NCT02039674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
Study NCT02039674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
Study NCT02039674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
Study NCT02039674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV on Day 1 of each 3-week cycle
Study NCT02989129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
Study NCT02989129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: 500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
Study NCT03981913 — intervention group
Intervention type: BEHAVIORAL
Intervention: Simon Task with high-density EEG recording
Description: The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected.
Study NCT01654003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR \< 90/min, CVP >8-12\< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
Study NCT01654003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIMIZED
Description: In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
Study NCT01332292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate
Description: Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
Study NCT02401204 — intervention group
Intervention type: OTHER
Intervention: Longitudinal surveillance study
Description: Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected.
Study NCT01621867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pGM169/GL67A
Description: 5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
Study NCT01621867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
Study NCT04375176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2
Description: Phenotypic and functional analysis of monocytes and NK cells
Study NCT03634267 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy
Study NCT03634267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan
Study NCT02301481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: 45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
Study NCT02301481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
Study NCT02301481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery, preferred D2 lymphadenectomy
Study NCT02301481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery, preferred D2 lymphadenectomy
Study NCT02301481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
Study NCT02301481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX
Description: SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
Study NCT02759991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hecolin
Description: 0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
Study NCT02759991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hepa-B
Description: 1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
Study NCT02082106 — intervention group
Intervention type: OTHER
Intervention: Alpine skiing
Study NCT02082106 — intervention group
Intervention type: OTHER
Intervention: cross country skiing
Study NCT02082106 — intervention group
Intervention type: OTHER
Intervention: Indoor training (cycling)
Study NCT03475329 — intervention group
Intervention type: OTHER
Intervention: adenotonsillectomy
Description: adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
Study NCT03023163 — intervention group
Intervention type: OTHER
Intervention: Longitudinal
Description: Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
Study NCT02994693 — intervention group
Intervention type: DEVICE
Intervention: OFDI capsule imaging
Description: Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
Study NCT02533726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Turning
Description: Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
Study NCT02533726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Practices
Description: Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
Study NCT02533726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Sensor
Description: A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
Study NCT02533726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Sensor
Description: A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
Study NCT04608734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Description: The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
Study NCT04608734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal midazolam
Description: Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
Study NCT02845531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator
Description: Implantable Cardioverter Defibrillator and Optimal Medical Therapy
Study NCT02845531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Study NCT03527719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Village-doctor-led multifaceted intervention
Description: * Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension~* Using hypertension control rate as one of the metrics for incentive supplements to village doctors~* Providing discounted or free antihypertensive medications to patients with hypertension~* Training village doctors to measure blood pressure according to a standard protocol~* Training village doctors to use a simple stepwise protocol for hypertension treatment~* Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence~* Providing free blood-pressure monitor and training to patients for home blood pressure measurement~* Encouraging lifestyle change and medication adherence~* Connecting patients through WeChat or telephone for group social support
Study NCT02552862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx®
Description: Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.